Michael Ehlert, MD
Urogynecology and Reconstructive Pelvic Surgery · Woodbury, MNNPI 1649447368
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $107,524 of the $150,776 with a category attached, or 71.3%. Coloplast accounts for 67.7% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $40,177, 3.3 times the $12,027 reported in 2019. Among urogynecology and reconstructive pelvic surgery clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $505.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$102K
- Boston Scientific$27K
- Laborie Medical Technologies Corp.$9K
- Valencia Technologies Corporation$6K
- Medtronic$5K
- Bluewind Medical$962
- plus $1K from 12 others
Across 48 payments — averaging $3863.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$46K
- Bluewind Medical$38K
- Urotronic, Inc$32K
- Boston Scientific$30K
- Laborie Medical Technologies Corp.$29K
- Axonics, Inc.$10K
What the payments were for
- Consulting fees$107,52471%
- Speaking & faculty fees$11,5138%
- Travel & lodging$8,2535%
- Food & beverage$10,0357%
- Education$13,4529%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 116 | $102,112 |
| Boston Scientific | 43 | $26,563 |
| Laborie Medical Technologies Corp. | 18 | $8,541 |
| Valencia Technologies Corporation | 13 | $5,922 |
| Medtronic(2 entities) | 57 | $5,242 |
| Bluewind Medical | 8 | $962 |
| Axonics, Inc. | 19 | $849 |
| Caldera Medical, Inc | 2 | $147 |
| AbbVie | 7 | $107 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $56 |
| Coopersurgical, Inc. | 2 | $54 |
| Astellas Pharma US Inc | 3 | $52 |
| Teleflex LLC | 3 | $50 |
| SRS Medical Systems, Inc. | 1 | $40 |
| Convatec Inc. | 1 | $24 |
| Merck | 1 | $19 |
| Olympus America Inc. | 1 | $19 |
| Blue Earth Diagnostics | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$86,930
- Advantage System$11,528
- TITAN$8,000
- Axonics$7,486
- eCoin Device Kit$5,507
- Optilume Urethral Drug Coated Balloon$4,200
- GENERAL - THERAPIES$2,731
- INTERSTIM$2,580
- GENERAL PELVIC ORGAN PROLAPSE$2,460
- ADVANTAGE$1,350
- RENOVA$819
- GENERAL KIDNEY STONE DISEASE$750
- Saffron$198
- RESTORELLE$150
How this compares
$150,776 in reported general payments places this provider in the 95th percentile of 22 urogynecology and reconstructive pelvic surgery providers in Minnesota.
See all urogynecology and reconstructive pelvic surgery providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 228 | $149,708 |
| GemtesaVibegron | 92 | $61,348 |
| Methenamine Hippurate | 156 | $12,936 |
| Mirabegron ErMirabegron | 12 | $7,886 |
| Trospium Chloride ErTrospium Chloride | 21 | $5,931 |
| Estradiol | 60 | $2,774 |
| Solifenacin Succinate | 82 | $2,718 |
| Oxybutynin Chloride ErOxybutynin Chloride | 120 | $2,429 |
| Trospium Chloride | 31 | $2,221 |
| Tolterodine Tartrate ErTolterodine Tartrate | 18 | $1,841 |
| Trimethoprim | 26 | $1,624 |
| Desmopressin Acetate | 32 | $1,608 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 164 | $1,506 |
| Tamsulosin Hcl | 104 | $1,186 |
| Finasteride | 60 | $947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $52 | $149,708228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 urogynecology and reconstructive pelvic surgery providers in Minnesota.
Other urogynecology and reconstructive pelvic surgery in Woodbury
- Emily MyerWoodbury$4K
- Sierra JansenWoodbury$930
- John GebhartRochester$11K
- John OcchinoRochester$6K
- Lioudmila SitnikovaEdina$6K
- Rahel NardosMinneapolis$4K
- Danielle WestenbergSt Louis Park$4K
- Christina SwallowSaint Paul$4K
- Jessica SelleDuluth$4K
- Derrick SandersonWinona$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.